{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:43:26Z","timestamp":1778568206181,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82160582"],"award-info":[{"award-number":["No. 82160582"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82160044 and No. 81960042"],"award-info":[{"award-number":["No. 82160044 and No. 81960042"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Yunnan Province Fundamental Research Project","award":["No. 202201AT070003"],"award-info":[{"award-number":["No. 202201AT070003"]}]},{"name":"The Scientific Research Project of Blood Center, the First Affiliated Hospital of Dali University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06062-7","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T05:36:16Z","timestamp":1730698576000},"page":"5817-5833","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["MiR-525-5p modulates cell proliferation, cell cycle, and apoptosis in Burkitt\u2019s lymphoma by targeting MyD88 and regulating the NF-\u03baB signaling pathway"],"prefix":"10.1007","volume":"103","author":[{"given":"Yan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiurong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"issue":"11","key":"6062_CR1","first-page":"1183","volume":"13","author":"K Fukui","year":"1985","unstructured":"Fukui K, Takeda S, Sadamoto K, Koike S, Okabe K, Toki H, Moriwaki S (1985) [A case of Burkitt\u2019s lymphoma with total ophthalmoplegia]. No Shinkei Geka 13(11):1183\u20131189","journal-title":"No Shinkei Geka"},{"issue":"3","key":"6062_CR2","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood.V93.3.1124","volume":"93","author":"ES Jaffe","year":"1999","unstructured":"Jaffe ES, Diebold J, Harris NL, Muller-Hermelink HK, Flandrin G, Vardiman JW (1999) Burkitt\u2019s lymphoma: a single disease with multiple variants. Blood 93(3):1124The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues","journal-title":"Blood"},{"issue":"4","key":"6062_CR3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1634\/theoncologist.11-4-375","volume":"11","author":"JA Ferry","year":"2006","unstructured":"Ferry JA (2006) Burkitt\u2019s lymphoma: clinicopathologic features and differential diagnosis. Oncologist 11(4):375\u2013383","journal-title":"Oncologist"},{"issue":"1","key":"6062_CR4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41572-022-00404-3","volume":"8","author":"C L\u00f3pez","year":"2022","unstructured":"L\u00f3pez C, Burkhardt B, Chan JKC, Leoncini L, Mbulaiteye SM, Ogwang MD, Orem J, Rochford R, Roschewski M, Siebert R (2022) Burkitt lymphoma. Nat Rev Dis Primers 8(1):78","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"6062_CR5","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1080\/10428194.2020.1747068","volume":"61","author":"AS Zayac","year":"2020","unstructured":"Zayac AS, Olszewski AJ (2020) Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy. Leuk Lymphoma 61(8):1784\u20131796","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"6062_CR6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrg2843","volume":"11","author":"J Krol","year":"2010","unstructured":"Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11(9):597\u2013610","journal-title":"Nat Rev Genet"},{"issue":"3","key":"6062_CR7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tcb.2006.12.007","volume":"17","author":"RS Pillai","year":"2007","unstructured":"Pillai RS, Bhattacharyya SN, Filipowicz W (2007) Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17(3):118\u2013126","journal-title":"Trends Cell Biol"},{"issue":"3","key":"6062_CR8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16(3):203\u2013222","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"6062_CR9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3233\/CBM-160598","volume":"16","author":"M Cybula","year":"2016","unstructured":"Cybula M, Wieteska \u023d, J\u00f3zefowicz-Korczy\u0144ska M, Karbownik MS, Grzelczyk WL, Szemraj J (2016) New miRNA expression abnormalities in laryngeal squamous cell carcinoma. Cancer Biomark 16(4):559\u2013568","journal-title":"Cancer Biomark"},{"key":"6062_CR10","doi-asserted-by":"crossref","first-page":"9957","DOI":"10.2147\/OTT.S257951","volume":"13","author":"P Xie","year":"2020","unstructured":"Xie P, Han Q, Liu D, Yao D, Lu X, Wang Z, Zuo X (2020) Mir-525-5p modulates proliferation and Epithelial-Mesenchymal Transition of Glioma by Targeting Stat-1. Onco Targets Ther 13:9957\u20139966","journal-title":"Onco Targets Ther"},{"issue":"8","key":"6062_CR11","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1007\/s10620-019-05916-9","volume":"65","author":"M Chen","year":"2020","unstructured":"Chen M, Liu LX (2020) MiR-525-5p repressed metastasis and Anoikis Resistance in Cervical Cancer via blocking UBE2C\/ZEB1\/2 Signal Axis. Dig Dis Sci 65(8):2442\u20132451","journal-title":"Dig Dis Sci"},{"issue":"2","key":"6062_CR12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1620\/tjem.2023.J027","volume":"260","author":"HH Tang","year":"2023","unstructured":"Tang HH (2023) MiR-640 and MiR-525-5p as Relapse-Associated MicroRNAs in systematically untreated individuals with low-risk primary breast Cancer. Tohoku J Exp Med 260(2):171\u2013179","journal-title":"Tohoku J Exp Med"},{"key":"6062_CR13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.12703\/P6-97","volume":"6","author":"J Deguine","year":"2014","unstructured":"Deguine J, Barton GM (2014) MyD88: a central player in innate immune signaling. F1000Prime Rep 6:97","journal-title":"F1000Prime Rep"},{"issue":"7332","key":"6062_CR14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H et al (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470(7332):115\u2013119","journal-title":"Nature"},{"key":"6062_CR15","doi-asserted-by":"crossref","unstructured":"Turi M, Anilkumar Sithara A, Hofmanov\u00e1 L, \u017dihala D, Radhakrishnan D, Vdovin A, Kn\u00e1pkov\u00e1 S, \u0160ev\u010d\u00edkov\u00e1 T, Chyra Z, Jel\u00ednek T et al (2023) Transcriptome analysis of diffuse large B-Cell lymphoma cells inducibly expressing MyD88 L265P mutation identifies upregulated CD44, LGALS3, NFKBIZ, and BATF as downstream targets of oncogenic NF-\u03baB signaling. Int J Mol Sci 24(6)","DOI":"10.3390\/ijms24065623"},{"issue":"7092","key":"6062_CR16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature04870","volume":"441","author":"M Karin","year":"2006","unstructured":"Karin M (2006) Nuclear factor-kappab in cancer development and progression. Nature 441(7092):431\u2013436","journal-title":"Nature"},{"issue":"1","key":"6062_CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","volume":"5","author":"H Yu","year":"2020","unstructured":"Yu H, Lin L, Zhang Z, Zhang H, Hu H (2020) Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther 5(1):209","journal-title":"Signal Transduct Target Ther"},{"key":"6062_CR18","unstructured":"Takeda T, Tsubak M, Genno S, Matsuda T, Yamamoto Y, Ueda E, Imano M, Satou T, Nishida S (2020) CD49d and CD49e induce cell adhesion-mediated drug resistance through the nuclear factor-\u03baB pathway in Burkitt lymphoma. J Physiol Pharmacol 71(4)"},{"key":"6062_CR19","doi-asserted-by":"crossref","unstructured":"Mcgeary SE, Lin KS, Shi CY, Pham TM, Bisaria N, Kelley GM, Bartel DP (2019) The biochemical basis of microRNA targeting efficacy. Science 366(6472)","DOI":"10.1126\/science.aav1741"},{"issue":"D1","key":"6062_CR20","doi-asserted-by":"crossref","first-page":"D127","DOI":"10.1093\/nar\/gkz757","volume":"48","author":"Y Chen","year":"2020","unstructured":"Chen Y, Wang X (2020) miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res 48(D1):D127\u2013d131","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"6062_CR21","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstr\u00f6m-Lindberg E, Tefferi A et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937\u2013951","journal-title":"Blood"},{"issue":"5","key":"6062_CR22","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/bjh.16461","volume":"189","author":"ML Moleti","year":"2020","unstructured":"Moleti ML, Testi AM, Fo\u00e0 R (2020) Treatment of relapsed\/refractory paediatric aggressive B-cell non-hodgkin lymphoma. Br J Haematol 189(5):826\u2013843","journal-title":"Br J Haematol"},{"key":"6062_CR23","doi-asserted-by":"crossref","unstructured":"Klener P, Klanova M (2020) Drug Resistance in Non-hodgkin Lymphomas. Int J Mol Sci 21(6)","DOI":"10.3390\/ijms21062081"},{"issue":"2","key":"6062_CR24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/path.2807","volume":"223","author":"D De Jong","year":"2011","unstructured":"De Jong D, Balagu\u00e9 Ponz O (2011) The molecular background of aggressive B cell lymphomas as a basis for targeted therapy. J Pathol 223(2):274\u2013282","journal-title":"J Pathol"},{"issue":"1","key":"6062_CR25","first-page":"89","volume":"13","author":"B Han","year":"2020","unstructured":"Han B, Wang S, Zhao H (2020) MicroRNA-21 and microRNA-155 promote the progression of Burkitt\u2019s lymphoma by the PI3K\/AKT signaling pathway. Int J Clin Exp Pathol 13(1):89\u201398","journal-title":"Int J Clin Exp Pathol"},{"key":"6062_CR26","doi-asserted-by":"crossref","unstructured":"Niu F, Dzikiewicz-Krawczyk A, Koerts J, De Jong D, Wijenberg L, Fernandez Hernandez M, Slezak-Prochazka I, Winkle M, Kooistra W, Van Der Sluis T et al (2020) MiR-378a-3p is critical for Burkitt Lymphoma Cell Growth. Cancers (Basel) 12(12)","DOI":"10.3390\/cancers12123546"},{"issue":"6","key":"6062_CR27","doi-asserted-by":"crossref","first-page":"9652","DOI":"10.1002\/jcp.27652","volume":"234","author":"D Zhang","year":"2019","unstructured":"Zhang D, Wei Y, Zhou J, Wang G, Xiao L, Xu J, Wei N, Li W, Zhang M (2019) miR-150 might inhibit cell proliferation and promote cell apoptosis by targeting LMO4 in Burkitt lymphoma. J Cell Physiol 234(6):9652\u20139662","journal-title":"J Cell Physiol"},{"issue":"5","key":"6062_CR28","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.sjbs.2018.05.010","volume":"25","author":"W Wang","year":"2018","unstructured":"Wang W, Lin P, Yao H, Jia X, Sun J, Feng L (2018) MicroRNA-4728 serves as a suppressor and antagonist of oncogenic MAPK in Burkitt lymphoma. Saudi J Biol Sci 25(5):982\u2013985","journal-title":"Saudi J Biol Sci"},{"key":"6062_CR29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.semcancer.2021.03.014","volume":"83","author":"S Peixoto Da Silva","year":"2022","unstructured":"Peixoto Da Silva S, Caires HR, Bergantim R, Guimar\u00e3es JE, Vasconcelos MH (2022) miRNAs mediated drug resistance in hematological malignancies. Semin Cancer Biol 83:283\u2013302","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"6062_CR30","doi-asserted-by":"crossref","first-page":"18077","DOI":"10.3390\/ijms160818077","volume":"16","author":"K Troppan","year":"2015","unstructured":"Troppan K, Wenzl K, Pichler M, Pursche B, Schwarzenbacher D, Feichtinger J, Thallinger GG, Beham-Schmid C, Neumeister P, Deutsch A (2015) miR-199a and miR-497 are Associated with Better overall survival due to increased chemosensitivity in diffuse large B-Cell lymphoma patients. Int J Mol Sci 16(8):18077\u201318095","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6062_CR31","first-page":"64","volume":"53","author":"D Tan","year":"2023","unstructured":"Tan D, Wang S, Zhang P, Peng C, Wu T (2023) LncRNA SNHG12 decreases Non-small Cell Lung Cancer Cell sensitivity to cisplatin by repressing mir-525-5p and promoting XIAP. Ann Clin Lab Sci 53(1):64\u201375","journal-title":"Ann Clin Lab Sci"},{"issue":"1","key":"6062_CR32","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1080\/21655979.2021.1951929","volume":"12","author":"Y Yao","year":"2021","unstructured":"Yao Y, Li X, Cheng L, Wu X, Wu B (2021) Circular RNA FAT atypical cadherin 1 (circFAT1)\/microRNA-525-5p\/spindle and kinetochore-associated complex subunit 1 (SKA1) axis regulates oxaliplatin resistance in breast cancer by activating the notch and wnt signaling pathway. Bioengineered 12(1):4032\u20134043","journal-title":"Bioengineered"},{"key":"6062_CR33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13048-015-0178-7","volume":"8","author":"Y Zhan","year":"2015","unstructured":"Zhan Y, Xiang F, Wu R, Xu J, Ni Z, Jiang J, Kang X (2015) MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88. J Ovarian Res 8:48","journal-title":"J Ovarian Res"},{"issue":"5","key":"6062_CR34","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/tox.22891","volume":"35","author":"Q Chen","year":"2020","unstructured":"Chen Q, Luo J, Wu C, Lu H, Cai S, Bao C, Liu D, Kong J (2020) The miRNA-149-5p\/MyD88 axis is responsible for ursolic acid-mediated attenuation of the stemness and chemoresistance of non-small cell lung cancer cells. Environ Toxicol 35(5):561\u2013569","journal-title":"Environ Toxicol"},{"key":"6062_CR35","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fonc.2019.00501","volume":"9","author":"F Xiang","year":"2019","unstructured":"Xiang F, Fan Y, Ni Z, Liu Q, Zhu Z, Chen Z, Hao W, Yue H, Wu R, Kang X (2019) Ursolic acid reverses the chemoresistance of breast Cancer cells to Paclitaxel by Targeting MiRNA-149-5p\/MyD88. Front Oncol 9:501","journal-title":"Front Oncol"},{"key":"6062_CR36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.gene.2019.02.066","volume":"700","author":"L Zhang","year":"2019","unstructured":"Zhang L, Chen T, Yan L, Xu H, Wang Y, Li Y, Wang H, Chen S, Wang W, Chen C et al (2019) MiR-155-3p acts as a tumor suppressor and reverses paclitaxel resistance via negative regulation of MYD88 in human breast cancer. Gene 700:85\u201395","journal-title":"Gene"},{"issue":"3","key":"6062_CR37","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1159\/000373941","volume":"35","author":"B Song","year":"2015","unstructured":"Song B, Zhang C, Li G, Jin G, Liu C (2015) MiR-940 inhibited pancreatic ductal adenocarcinoma growth by targeting MyD88. Cell Physiol Biochem 35(3):1167\u20131177","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"6062_CR38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10238-020-00625-4","volume":"20","author":"Y Sheng","year":"2020","unstructured":"Sheng Y, Hu R, Zhang Y, Luo W (2020) MicroRNA-4317 predicts the prognosis of breast cancer and inhibits tumor cell proliferation, migration, and invasion. Clin Exp Med 20(3):417\u2013425","journal-title":"Clin Exp Med"},{"issue":"6","key":"6062_CR39","first-page":"809","volume":"9","author":"Y Tang","year":"2021","unstructured":"Tang Y, Tang Z, Yang J, Liu T, Tang Y (2021) MicroRNA-7-5p inhibits Migration, Invasion and Metastasis of Intrahepatic Cholangiocarcinoma by inhibiting MyD88. J Clin Transl Hepatol 9(6):809\u2013817","journal-title":"J Clin Transl Hepatol"},{"issue":"12","key":"6062_CR40","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1182\/blood.2020004918","volume":"137","author":"X Yu","year":"2021","unstructured":"Yu X, Li W, Deng Q, Liu H, Wang X, Hu H, Cao Y, Xu-Monette ZY, Li L, Zhang M et al (2021) MYD88 L265P elicits mutation-specific ubiquitination to drive NF-\u03baB activation and lymphomagenesis. Blood 137(12):1615\u20131627","journal-title":"Blood"},{"issue":"11","key":"6062_CR41","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s00262-018-2242-9","volume":"67","author":"ANR Weber","year":"2018","unstructured":"Weber ANR, Cardona Gloria Y, \u00c7\u0131nar \u00d6, Reinhardt HC, Pezzutto AWolz OO (2018) Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities. Cancer Immunol Immunother 67(11):1797\u20131807","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"6062_CR42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.hemonc.2020.10.003","volume":"14","author":"R Shekhar","year":"2021","unstructured":"Shekhar R, Naseem S, Binota J, Varma N, Malhotra P (2021) Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm. Hematol Oncol Stem Cell Ther 14(3):231\u2013239","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"7","key":"6062_CR43","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.humpath.2012.10.026","volume":"44","author":"JW Choi","year":"2013","unstructured":"Choi JW, Kim Y, Lee JH, Kim YS (2013) MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Hum Pathol 44(7):1375\u20131381","journal-title":"Hum Pathol"},{"key":"6062_CR44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biopha.2018.07.139","volume":"107","author":"L Wang","year":"2018","unstructured":"Wang L, Yu K, Zhang X, Yu S (2018) Dual functional roles of the MyD88 signaling in colorectal cancer development. Biomed Pharmacother 107:177\u2013184","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"6062_CR45","first-page":"6203","volume":"37","author":"E Shiratori","year":"2017","unstructured":"Shiratori E, Itoh M, Tohda S (2017) MYD88 inhibitor ST2825 suppresses the growth of Lymphoma and Leukaemia cells. Anticancer Res 37(11):6203\u20136209","journal-title":"Anticancer Res"},{"issue":"7","key":"6062_CR46","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2006-07-025809","volume":"109","author":"PJ Jost","year":"2007","unstructured":"Jost PJ, Ruland J (2007) Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109(7):2700\u20132707","journal-title":"Blood"},{"issue":"9","key":"6062_CR47","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/1535370213498985","volume":"238","author":"SA Maxwell","year":"2013","unstructured":"Maxwell SA, Mousavi-Fard S (2013) Non-hodgkin\u2019s B-cell lymphoma: advances in molecular strategies targeting drug resistance. Exp Biol Med (Maywood) 238(9):971\u2013990","journal-title":"Exp Biol Med (Maywood)"},{"issue":"3","key":"6062_CR48","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.ymthe.2020.11.026","volume":"29","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Zhao X, Wang D, Moreira D, Su YL, Alcantara M, Swiderski P, Wong J, Hui S, Forman S et al (2021) Targeted in vivo delivery of NF-\u03baB decoy inhibitor augments sensitivity of B Cell Lymphoma to Therapy. Mol Ther 29(3):1214\u20131225","journal-title":"Mol Ther"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06062-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06062-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06062-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:12:53Z","timestamp":1735866773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06062-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6062"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06062-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"assertion":[{"value":"11 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of the First Affiliated Hospital of Dali University (approval no. DFY20210910001; Yunnan, China) and was conducted according to the principles of the Helsinki Declaration. Individual consent was not necessary for this study in accordance with the national legislation and the institutional requirements because the study used existing clinical data in the medical record system and the identity of the patients was not disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}